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pulsed administration of a maximal tolerated dose. 
The metronomic dosing concept is explored, and its 
possible advantages are discussed.
In the Radiation Oncology section, measure-
ment of quality of life in cancer patients receiving 
palliative radiotherapy for symptomatic lung cancer 
is discussed. This important role for radiotherapy 
departments is expanding with the inception of rapid-
response programs serving the community. (A paper 
in issue 3 of the current volume will discuss treat-
ment delivery by image-guided intensity-modulated 
radiotherapy for this group of patients, a technique 
hitherto typically reserved for more radical and cura-
tive treatment options.)
In the new Psychosocial Oncology section, 
Drs. Robert Rutledge and Lynne Robinson argue for 
greater integration of hospital-based cancer care with 
established community services and organizations. 
Meanwhile, two of the journal’s regular features 
look at new and intriguing oncologic treatment pos-
sibilities. Updates and Developments in Oncology 
presents a discussion of electroporation-based cancer 
treatment approaches that are currently undergoing 
intensive investigation in the fields of drug delivery 
and gene therapy for the electrochemotherapy of 
tumours. This technique seeks to enhance the trans-
portation of chemotherapeutic drugs across the cell 
membrane to improve the therapeutic ratio. And in 
the Drug Development in Contemporary Oncology 
section, the potential role of inhibitors of the cyclin-
dependent kinases (c d k s), a new class of anticancer 
agents, is explored—specifically, the use of these 
agents in combination with traditional cytotoxic 
chemotherapy. In combination, these new agents ap-
pear to have potential to assist in overcoming drug 
resistance, thereby improving cytotoxic efficacy.
“Privatization is not an answer to health care access 
problems, increased public funding is,” or so claims 
Ervin B. Podgorsak in the first of our guest editorials 
in this issue of Current Oncology. To rescue a Canadian 
health care system that is of high quality, but that has 
problems with access and cost, the author suggests 
an immediate cash bailout of between 15% and 20% 
of funding to meet stated goals—a solution possibly 
difficult to envisage in these economic times, no mat-
ter the eloquence of the argument.
“Privately run health care ... results in a U.S.-
type two-tiered and socially unjust medical system 
in which access to health care depends on patients’ 
ability to pay for services rather than on the need for 
them.” This is a pivotal argument in the manuscript 
and one that I have always had some difficulty with. 
If someone elects to pay for their arthroplasty in a 
private facility, then presumably one less individual 
is waitlisted elsewhere. A win–win.
Is it “fair” to allow this situation to happen? I 
don’t know the answer. Is it fair to force someone 
to wait for services that they can afford to purchase 
in the private domain, where it available? Perhaps 
we should attempt to improve the efficiency of the 
system, eliminate the appalling cost of waste and 
duplication, adhere strictly to a policy of evidence-
based medicine, inject funds (if any are left after the 
banking fiascos), and expand private practice.
Also in this issue, a second guest editorial from 
Dr. Patricia Dobkin considers how a physician’s 
mindfulness may facilitate healing in the context of 
medical practice, and Dr. O. Graciela Scharovsky 
and her colleagues discuss the concept of metro-
nomic chemotherapy. This latter approach of chronic, 
equally spaced administration of generally low doses 
of various chemotherapeutic drugs without extended 
rest periods departs from the more conventional 